Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection

A point-of-care (POC) diagnostic is needed for both women and men to establish universal screening and surveillance for the number one, non-viral sexually transmitted infection (STI) caused by Trichomonas vaginalis. We developed a POC diagnostic for this STI using the MedMira Rapid Vertical Flow (RVF®) Technology test cartridge with a membrane that includes a Vertical procedural/reagent control line (referred to as CVL) and spotted with 1 µg of a 72.4-kDa truncated version of α-actinin called ACT::SOE3. This protein is a specific diagnostic target for antibody in sera of individuals with trichomoniasis. Serum antibody to ACT::SOE3 is a positive reaction with the test spot. Specificity of ACT::SOE3 was revealed with monoclonal antibodies (MAbs) generated to ACT::SOE3. Addition of negative control serum with MAb 67B reactive to ACT::SOE3 shows detection of both ACT::SOE3 and the CVL. Only positive sera of individuals had antibody reactive with ACT::SOE3 and detected the presence of the spot and the CVL. Negative control sera were unreactive with ACT::SOE3 and only showed the presence of the CVL. Importantly, to show proof-of-principle for POC application, ACT::SOE3 was detected with the positive patient sera spiked with whole blood. Finally, packaged cartridges stored with desiccant packs at 37 °C for one year gave identical results with the positive and negative human sera. Our results show the validity of this new POC serodiagnostic for this STI.

[1]  P. V. Van Caeseele,et al.  Laboratory evaluation of two point-of-care test kits for the identification of infectious syphilis. , 2022, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[2]  J. Ryu,et al.  Involvement of Macrophages in Proliferation of Prostate Cancer Cells Infected with Trichomonas vaginalis , 2021, The Korean journal of parasitology.

[3]  J. Ryu,et al.  Proliferation of Mouse Prostate Cancer Cells Inflamed by Trichomonas vaginalis , 2021, The Korean journal of parasitology.

[4]  J. Alderete.  Recombinant Protein of Immunogenic Metabolic Enzyme Epitopes of Trichomonas vaginalis are Common to Humans and Microorganisms , 2021, American Journal of Biomedical Science & Research.

[5]  Su-Jin Shin,et al.  Signaling Role of Adipocyte Leptin in Prostate Cell Proliferation Induced by Trichomonas vaginalis , 2021, The Korean journal of parasitology.

[6]  I. Spicknall,et al.  Incidence and Prevalence of Trichomonas vaginalis infection among persons aged 15-59: United States, 2018. , 2021, Sexually transmitted diseases.

[7]  J. Klausner,et al.  Point-of-Care Testing for Sexually Transmitted Infections: A Review of Recent Developments. , 2020, Archives of pathology & laboratory medicine.

[8]  J. Alderete.  Advancing Prevention of STIs by Developing Specific Serodiagnostic Targets: Trichomonas vginalis as a Model , 2020, International journal of environmental research and public health.

[9]  W. Luo,et al.  Performance evaluation of the MedMira reveal G4 LAB S/P and POC HIV antibody rapid screening tests using plasma and whole blood specimens. , 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[10]  A. Lagunes-Guillén,et al.  The effect of iron on Trichomonas vaginalis TvCP2: a cysteine proteinase found in vaginal secretions of trichomoniasis patients , 2020, Parasitology.

[11]  D. Soper,et al.  Diagnosis, Treatment, Follow-up, and Persistence of Trichomonas vaginalis in Women 45 Years and Older According to HIV Status: A 10-Year Retrospective Cohort , 2020, Sexually transmitted diseases.

[12]  J. Ryu,et al.  IL-6 produced by prostate epithelial cells stimulated with Trichomonas vaginalis promotes proliferation of prostate cancer cells by inducing M2 polarization of THP-1-derived macrophages , 2020, PLoS neglected tropical diseases.

[13]  J. Ryu,et al.  Inflammatory mediators of prostate epithelial cells stimulated with Trichomonas vaginalis promote proliferative and invasive properties of prostate cancer cells , 2019, The Prostate.

[14]  N. Low,et al.  Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016 , 2019, Bulletin of the World Health Organization.

[15]  J. Ryu,et al.  Experimental rat prostatitis caused by Trichomonas vaginalis infection , 2018, The Prostate.

[16]  M. Vaneechoutte,et al.  Trichomonas vaginalis and HIV infection acquisition: a systematic review and meta-analysis , 2018, Sexually Transmitted Infections.

[17]  D. Soper,et al.  Unexpected High Rates of Persistent Trichomonas vaginalis Infection in a Retrospective Cohort of Treated Pregnant Women , 2019, Sexually transmitted diseases.

[18]  T. Quinn,et al.  Prevalence and Correlates of Trichomonas vaginalis Infection Among Men and Women in the United States , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  C. Muzny.  Why Does Trichomonas vaginalis Continue to be a "Neglected" Sexually Transmitted Infection? , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  R. Peeling,et al.  Advancing prevention of sexually transmitted infections through point-of-care testing: target product profiles and landscape analysis , 2017, Sexually Transmitted Infections.

[21]  M. Kamb,et al.  Syphilis testing practices in the Americas , 2017, Tropical medicine & international health : TM & IH.

[22]  R. Peeling,et al.  Rapid and point-of-care tests for the diagnosis of Trichomonas vaginalis in women and men , 2017, Sexually Transmitted Infections.

[23]  J. Ryu,et al.  Interaction between Trichomonas vaginalis and the Prostate Epithelium , 2017, The Korean journal of parasitology.

[24]  C. Brosseau,et al.  Development of a SERS-Based Rapid Vertical Flow Assay for Point-of-Care Diagnostics. , 2017, Analytical chemistry.

[25]  J. Alderete.  Epitopes within recombinant α-actinin protein is serodiagnostic target for Trichomonas vaginalis sexually transmitted infections , 2017, Heliyon.

[26]  C Jessica E Metcalf,et al.  Use of serological surveys to generate key insights into the changing global landscape of infectious disease , 2016, The Lancet.

[27]  Marleen Temmerman,et al.  Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting , 2015, PloS one.

[28]  D. Dessì,et al.  Kinetics of circulating antibody response to Trichomonas vaginalis: clinical and diagnostic implications , 2015, Sexually Transmitted Infections.

[29]  S. M. Rogers,et al.  Epidemiology of Undiagnosed Trichomoniasis in a Probability Sample of Urban Young Adults , 2014, PloS one.

[30]  J. Alderete,et al.  Epitopes of the Highly Immunogenic Trichomonas vaginalis α-Actinin Are Serodiagnostic Targets for Both Women and Men , 2013, Journal of Clinical Microbiology.

[31]  P. Kissinger,et al.  Trichomoniasis and HIV interactions: a review , 2013, Sexually Transmitted Infections.

[32]  J. May,et al.  Serological survey of HIV and syphilis in pregnant women in Madagascar , 2013, Tropical medicine & international health : TM & IH.

[33]  M. Stampfer,et al.  Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. , 2009, Journal of the National Cancer Institute.

[34]  P. Goodman,et al.  Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial , 2009, International journal of cancer.

[35]  A. Kucknoor,et al.  Glyceraldehyde-3-Phosphate Dehydrogenase Is a Surface-Associated, Fibronectin-Binding Protein of Trichomonas vaginalis , 2009, Infection and Immunity.

[36]  C. Malotte,et al.  Persistent, undetected Trichomonas vaginalis infections? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  M. Kalish,et al.  Alternative Algorithms for Human Immunodeficiency Virus Infection Diagnosis Using Tests That Are Licensed in the United States , 2008, Journal of Clinical Microbiology.

[38]  W. Willett,et al.  Plasma Antibodies against Trichomonas vaginalis and Subsequent Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[39]  S. Pinkerton,et al.  Estimates of the Annual Number and Cost of New HIV Infections Among Women Attributable to Trichomoniasis in the United States , 2004, Sexually transmitted diseases.

[40]  H. Whitaker,et al.  Estimation of infectious disease parameters from serological survey data: the impact of regular epidemics , 2004, Statistics in medicine.

[41]  R. Ballard,et al.  Evaluation of Xenostrip-Tv, a Rapid Diagnostic Test for Trichomonas vaginalis Infection , 2004, Journal of Clinical Microbiology.

[42]  Stuart Berman,et al.  Perspectives on Sexual and Reproductive Health Sexually Transmitted Diseases among American Youth: Incidence and Prevalence Estimates, 2000 , 2022 .

[43]  P. Moodley,et al.  Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  S. Gregson,et al.  Enzyme immunoassay for urogenital trichomoniasis as a marker of unsafe sexual behaviour , 2001, Epidemiology and Infection.

[45]  P. Fiori,et al.  Identification of Trichomonas vaginalis α-Actinin as the Most Common Immunogen Recognized by Sera of Women Exposed to the Parasite , 1999 .

[46]  P. Kerndt,et al.  Trichomonas vaginalis and amplification of HIV-1 transmission , 1998, The Lancet.

[47]  M. Krohn,et al.  Trichomonas vaginalis Associated With Low Birth Weight and Preterm Delivery , 1997, Sexually transmitted diseases.

[48]  P. Piot,et al.  Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. , 1993 .

[49]  J. Alderete,et al.  Proteinases of Trichomonas vaginalis: antibody response in patients with urogenital trichomoniasis , 1992, Parasitology.

[50]  J. Alderete,et al.  Antibody in sera of patients infected with Trichomonas vaginalis is to trichomonad proteinases. , 1991, Genitourinary medicine.

[51]  J. Alderete,et al.  The regulation by iron of the synthesis of adhesins and cytoadherence levels in the protozoan Trichomonas vaginalis , 1991, The Journal of experimental medicine.

[52]  J. Alderete,et al.  Phenotypes and protein-epitope phenotypic variation among fresh isolates of Trichomonas vaginalis , 1987, Infection and immunity.

[53]  J. Alderete.  Identification of immunogenic and antibody-binding membrane proteins of pathogenic Trichomonas vaginalis , 1983, Infection and immunity.

[54]  J. Alderete.  Antigen analysis of several pathogenic strains of Trichomonas vaginalis , 1983, Infection and immunity.

[55]  P. Ward.  THE INFLAMMATORY MEDIATORS * , 1974, Annals of the New York Academy of Sciences.

[56]  C. Dolea,et al.  World Health Organization , 1949, International Organization.